(Q35936039)

11 August 2017

0 references

1 reference

title

Palliative chemotherapy for advanced gastric cancer (English)

1 reference

11 August 2017

1 reference

S S Wöhrer

1

1 reference

11 August 2017

M Raderer

series ordinal

2

1 reference

11 August 2017

M Hejna

series ordinal

3

1 reference

11 August 2017

publication date

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

15

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

1585-1595

1 reference

11 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

A review of chemotherapy in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Report on nationwide pooled data and cohort investigation in UFT phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Results of treatment of malignant tumors with ftorafur

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDH422

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDH422

1 reference

11 August 2017

1 reference